Executive Summary
All nine filings in this stream point to a concentrated wave of Nasdaq and NYSE listing-compliance distress rather than bankruptcy, going-concern, or delisting-completed events in the strict sense. Three distinct failure modes dominate: stockholders' equity deficiencies (Lunai Bioworks, Dragonfly Energy, STEM, Polar Power), minimum bid price breaches (Akebia, Laser Photonics, Medicus Pharma, Innventure), and market-value-of-listed-securities shortfalls (Century Casinos).
Lunai Bioworks is the most advanced distress case, having reported a $(9.0)M stockholders' deficit and voluntarily chosen delisting with trading suspension on October 30, 2026 and no planned OTC quotation. Dragonfly's deficit is much smaller at $(184,000) but it has a hard December 31, 2026 evidence deadline. Polar Power illustrates the cure-by-financing pattern: an estimated $2.9M pro forma equity was largely produced by insider and related-party conversions and dilutive PIK-bearing preferred paper, so the compliance is fragile. Medicus Pharma regained bid-price compliance on October 23, 2026 after ten days above $1.00 following a delisting determination, showing that short-term price recovery can moot delisting. Because the enriched period-over-period, insider, capital allocation, and forward-looking fields were not populated for these filings, quantitative trend comparisons across companies are not available; the analysis below relies on the stated filing facts and dates.
Materiality, sentiment, and priority are scored by Gunpowder’s analysis pipeline. How we score filings →
Filing types in this digest: 8-K
Tracking the trend? Catch up on the prior US Corporate Distress Financial Stress SEC Filings digest from October 22, 2026.
Investment Signals (9)
- Lunai Bioworks (LNAI) (BEARISH)▲
Stockholders' deficit of $(9,024,946) at FY2026 year-end, Board chose voluntary delisting with suspension October 30, 2026 and no OTC quotation planned, implying a likely loss of any tradable market
- Dragonfly Energy (DFLI) (BEARISH)▲
Stockholders' deficit of $(184,000) at June 30, 2026, failing both market value ($35M) and net income ($500K) alternatives, with compliance evidence due December 31, 2026
- Polar Power (POLA) (MIXED)▲
Estimated pro forma equity of about $2.9M (unaudited) is above the $2.5M threshold, but related-party conversions (CEO Arthur Sams $614,700 plus $161,276 notes) drove it, so the cure is not organic
- Medicus Pharma (MDCXW) (MIXED)▲
Regained bid-price compliance on October 23, 2026 after ten consecutive business days at or above $1.00 (October 12 to 23), mooting the October 20 delisting determination, yet it still fails the $5M equity test and management cautions no assurance of continuation
- Akebia Therapeutics (AKBA) (BEARISH)▲
Bid price below $1.00 for 30 business days triggered a notice on October 21, 2026, with a 180-day cure window to April 19, 2027 and a possible reverse split route
- Laser Photonics (LASE) (BEARISH)▲
Bid price notice received October 20, 2026, cure deadline April 19, 2027, with a second 180-day period possible only if public float value and other initial listing standards are met
- Innventure (INV) (BEARISH)▲
Bid price notice dated October 23, 2026 covering 30 business days ended October 22; initial cure deadline April 21, 2027, extension requires transfer to Nasdaq Capital Market
- Century Casinos (CNTY) (BEARISH)▲
MVLS below $35M for 30 consecutive business days per notice of October 19, 2026; cure deadline April 19, 2027, with an alternative route via stockholders' equity or net income tests
- STEM, Inc. (STEM) ↓ (MIXED)▲
NYSE non-compliance letter received October 20, 2026 on both $50M average market cap and $50M equity tests; stock continues trading during an 18-month cure window subject to an accepted business plan due within 45 days
Risk Flags (9)
- Lunai Bioworks / Delisting Without Market↓ [HIGH RISK]▼
Board approved voluntary delisting, suspension expected October 30, 2026, Form 25 around November 2, 2026, and no OTC quotation intended, so holders may have no liquid exit; mandatory Hearings Panel Monitor under Rule 5815(d)(4)(B) was a contributing factor
- Stockholders' Equity Deficits Across Four Issuers [HIGH RISK]▼
Lunai ($(9.0)M), Dragonfly ($(0.18)M) and near-threshold Polar Power illustrate repeated failure of the $2.5M equity test, a sign of structural balance sheet weakness across small-cap listings
- Dragonfly Energy / Hard Deadline↓ [HIGH RISK]▼
Failure to evidence equity compliance in the period-end report for December 31, 2026 triggers a delisting notice; both alternative tests were unmet as of August 20, 2026
- Polar Power / Dilution and Quality of Cure↓ [HIGH RISK]▼
Conversion at a discount to VWAP, a 10% PIK dividend, and a senior perpetual Series A Preferred create ongoing dilution and make the $2.9M equity figure dependent on insider conversions and unaudited estimates, with compliance to be re-tested at the next periodic report
- Medicus Pharma / Reversal Risk↓ [MEDIUM RISK]▼
Delisting determination of October 20 was mooted only on October 23 by a ten-day price run; the company says there is no assurance of continued compliance and it fails the $5M equity requirement, so relapse into a delisting determination is plausible
- Bid-Price Cluster (Akebia, Laser Photonics, Innventure) [MEDIUM RISK]▼
Three filings in one week all cite sub-$1.00 closing bid over 30 business days, with cure deadlines clustered around April 19-21, 2027, suggesting a broad small-cap price weakness and likely reverse-split activity
- Century Casinos / Market Value Erosion↓ [MEDIUM RISK]▼
MVLS below $35M is a market-cap-based failure, implying the equity has repriced sharply relative to the listing standard; cure depends on either price recovery or meeting equity or income tests, neither confirmed
- STEM / NYSE Market Cap and Equity Test↓ [MEDIUM RISK]▼
Simultaneous failure of average market cap ($50M) and stockholders' equity ($50M) tests on NYSE indicates balance sheet and valuation pressure together; the company states operations and SEC reporting are unaffected, but the 45-day business plan milestones will set measurable accountability
- Akebia / Hearings Dependence↓ [LOW-MEDIUM RISK]▼
Company says any eventual delisting may be appealed with no assurance of success and is evaluating reverse-split options, which would add near-term share count and price volatility
Opportunities (8)
- Medicus Pharma / Post-Moot Trading Setup↓ (OPPORTUNITY)◆
Confirmed ten-day compliance (October 12-23) with the delisting determination superseded gives a documented recovery window; a catalyst-driven stock could be traded around sustained closes above $1.00, although the company disclaims continued compliance
- Polar Power / Event-Driven Equity Entry↓ (OPPORTUNITY)◆
Compliance announcement is tied to a deadline of October 28, 2026 for public filing; the company says Nasdaq will re-test at the next periodic report, creating a defined verification event for those who can accept dilution risk
- Dragonfly Energy / Compliance Catalyst Window↓ (OPPORTUNITY)◆
With a December 31, 2026 evidence deadline and a documented compliance plan submitted October 5, 2026, the period-end report is a binary event; a shift toward positive net income or an equity raise would reverse the deficit before the window closes
- Akebia Therapeutics / Reverse Split Optionality↓ (OPPORTUNITY)◆
Company has a runway to April 19, 2027 and has stated it may consider a reverse split; a split would restore the price test but could be read as a signal, so timing of announcement is a catalyst to monitor
- Laser Photonics / Second Compliance Period Path↓ (OPPORTUNITY)◆
If the company meets the MVPHS and other initial listing standards (excluding bid price) and provides written intent to cure, it may gain a second 180-day period beyond April 19, 2027, extending the restructuring runway
- Innventure / Transfer-Based Extension↓ (OPPORTUNITY)◆
The additional 180-day period requires a transfer to Nasdaq Capital Market, which can be a credible governance step; if the company meets the listing conditions, the transfer buys runway through late 2027
- Century Casinos / Multiple Cure Routes↓ (OPPORTUNITY)◆
The company may regain compliance through MVLS, stockholders' equity, or net income under Rule 5550(b), giving three independent paths before April 19, 2027; a multi-route cure profile improves the probability of retention relative to single-test issuers
- STEM / 18-Month Cure Horizon↓ (OPPORTUNITY)◆
The NYSE 18-month cure window with quarterly milestones is one of the longer runways in this group, and the company says it is operating normally; if milestones are credibly met, the stock can re-rate on evidence of progress
Sector Themes (5)
- Listing-Standard Deficiencies Dominate Filings◆
All nine filings concern exchange deficiency notices rather than Chapter 11 or going-concern opinions; the stream's distress signal in this batch is primarily Nasdaq/NYSE compliance failure, with 4 equity-deficiency, 4 bid-price, and 1 MVLS-based notice among 9 issuers (one issuer, STEM, reports both market-cap and equity failures) [Implication: Investors should treat exchange notices as early-stage distress and watch for the transition to delisting or bankruptcy]
- Cure-by-Financing Pattern◆
Polar Power's compliance was produced by convertible notes, preferred stock, warrants, and an equity line, much of it from insiders; the cure is financing-driven rather than earnings-driven, with dilutive terms (PIK dividend, discount-to-VWAP conversion) [Implication: Equity-test compliance achieved this way tends to be temporary and sets up another test at the next periodic filing]
- Bid-Price Cure Deadlines Cluster in April 2027◆
Akebia (April 19, 2027), Laser Photonics (April 19, 2027), Innventure (April 21, 2027) and Century Casinos' MVLS cure (April 19, 2027) share nearly identical runway dates, implying similar notice timing and a shared window for reverse-split decisions [Implication: Expect a wave of reverse-split proposals or shareholder meeting notices in H1 2027]
- Delisting Path Versus Second-Period Eligibility◆
Medicus was denied a second compliance period for failing the $5M equity test, while Laser Photonics and Innventure may qualify if they meet market value and initial listing standards; eligibility for the second period, which depends on equity and float value, is the key differentiator between companies that retain listings and those that do not [Implication: Equity and public-float strength drive outcomes more than the bid price alone]
- Voluntary Delisting as an Exit Route◆
Lunai chose to delist voluntarily rather than contest, with no planned OTC quotation; this represents a distinct exit mode that leaves shareholders without a market, in contrast to the cure-period companies [Implication: For micro-cap issuers with deep deficits, the endgame may be illiquidity rather than a bankruptcy filing]
Watch List (8)
-
Suspension expected October 30, 2026, Form 25 on or about November 2, 2026, delisting effective around November 12, 2026; watch for Form 15 and any OTC or Pink quotation (none intended) [Date: Oct 30 - Nov 12, 2026]
-
Public filing evidencing equity compliance due on or before October 28, 2026, followed by Nasdaq monitoring at the next periodic report; watch for unaudited equity figures being restated and further conversions [Date: Oct 28, 2026]
-
Equity compliance must be evidenced in the report for December 31, 2026, with delisting notice risk if not met; watch the Q4 filing and any further financing [Date: Dec 31, 2026]
-
Must hold closing bid at or above $1.00 after regaining compliance on October 23, 2026; a fall below $1.00 would reopen the delisting process given no second-period eligibility [Date: ongoing from Oct 23, 2026]
-
Business plan due within 45 days of the October 20, 2026 letter (approximately December 4, 2026), with quarterly milestones to be reviewed by NYSE; watch NYSE acceptance and the Exhibit 99 press release follow-up [Date: approx. Dec 4, 2026]
-
Initial compliance deadline April 19, 2027; a reverse split decision or proxy filing is the key near-term event to watch, ahead of any second-period application [Date: by Apr 19, 2027]
-
Written notice of intent to cure and meeting of MVPHS and other standards must occur to qualify for a second 180-day period past April 19, 2027 [Date: by Apr 19, 2027]
-
Any transfer and related filing to secure the additional 180-day period must be completed before the April 21, 2027 initial deadline [Date: by Apr 21, 2027]
Filing Analyses
(9)
23-10-2026
Lunai Bioworks Inc. (Nasdaq: LNAI) received a Nasdaq Listing Qualifications letter on October 21, 2026 stating it no longer complies with Listing Rule 5550(b)(1), which requires minimum stockholders' equity of $2.5 million, after reporting a stockholders' deficit of $(9,024,946) in its FY2026 Form 10-K (fiscal year ended June 30, 2026). Rather than contest the determination, the Board approved voluntary delisting on October 22, 2026, with trading expected to be suspended on October 30, 2026 and delisting effective around November 12, 2026. The company does not intend to arrange over-the-counter quotation, so a trading market may not exist after Nasdaq suspension.
- · Company is subject to a mandatory Hearings Panel Monitor under Nasdaq Listing Rule 5815(d)(4)(B), which led Nasdaq staff to determine delisting
- · Company will not request a hearing and will not pursue OTC quotation for its common stock
- · Form 25 expected to be filed on or about November 2, 2026; Form 15 to suspend SEC reporting to follow, to the extent eligible
- · SEC reporting obligations continue unless and until terminated or suspended under SEC rules
23-10-2026
Dragonfly Energy Holdings Corp. disclosed that Nasdaq granted an extension through December 31, 2026 for the company to regain compliance with the $2.5 million minimum stockholders' equity requirement under Listing Rule 5550(b)(1). The company reported a stockholders' deficit of $(184,000) as of its June 30, 2026 Form 10-Q and did not meet the alternative market value ($35 million) or net income ($500,000) standards as of August 20, 2026. Failure to evidence compliance by December 31, 2026 could lead to delisting from the Nasdaq Capital Market.
- · Company received the initial Nasdaq deficiency letter on August 20, 2026, and submitted its compliance plan on October 5, 2026.
- · Under the extension, the company must file a public report evidencing equity compliance with the SEC and Nasdaq by December 31, 2026.
- · If compliance is not evidenced in the period-end report for December 31, 2026, Nasdaq staff will issue a delisting notice, and the company may appeal to a Nasdaq hearings panel.
- · The company is an emerging growth company and is headquartered in Reno, Nevada.
23-10-2026
STEM, Inc. received a non-compliance letter from the NYSE on October 20, 2026, after failing to meet Section 802.01B of the NYSE Listed Company Manual, which requires an average market capitalization of at least $50.0 million over 30 consecutive trading days and stockholders' equity of at least $50.0 million. The company must submit a business plan within 45 days of receiving the letter, with a path to regain compliance within 18 months, and its common stock continues to trade on the NYSE during the cure period subject to NYSE acceptance of the plan. The company states the non-compliance does not affect its ongoing business operations or SEC reporting obligations.
- · Company was notified by NYSE on October 19, 2026 of non-compliance and received the formal NYSE Letter on October 20, 2026
- · Business plan must identify specific quarterly milestones against which NYSE will evaluate progress
- · Company issued a press release on October 23, 2026 (Exhibit 99, furnished under Item 7.01, not deemed filed under Exchange Act Section 18)
23-10-2026
Akebia Therapeutics (Nasdaq: AKBA) received a Nasdaq deficiency letter on October 21, 2026, after its common stock closed below the $1.00 minimum bid price for 30 consecutive business days. The notice has no immediate effect on the listing; the company has an initial compliance period until April 19, 2027 (180 calendar days) to regain compliance by closing at or above $1.00 for at least 10 consecutive business days, with a possible second 180-day period if it qualifies and commits to a reverse stock split if necessary.
- · Nasdaq Listing Rule 5550(a)(2) bid price requirement was the basis of the deficiency notice
- · Company may appeal any eventual delisting determination to a Nasdaq Hearings Panel, with no assurance of success
- · Company stated it will monitor the bid price and evaluate options, which could include a reverse stock split
23-10-2026
Polar Power, Inc. (NASDAQ: POLA) disclosed it believes it has regained compliance with Nasdaq Listing Rule 5550(b)(1), which requires a minimum of $2.5 million in stockholders' equity, after a series of convertible note, preferred stock, warrant, and equity line financings. The Company estimates preliminary pro forma stockholders' equity of approximately $2.9 million as of the report date, but these figures are unaudited and subject to revision, and Nasdaq will continue monitoring compliance at the next periodic report, with delisting possible if compliance is not evidenced.
- · Nasdaq extension required a public filing demonstrating compliance on or before October 28, 2026
- · Equity was boosted largely by related-party and insider conversions, including CEO Arthur Sams converting $614,700 and a further $161,276 in notes
- · Financing terms include a 10% PIK dividend, perpetual Series A Preferred senior to common stock, and conversion at a discount to VWAP that can be dilutive
- · Company stated the preferred stock and warrants may be subject to reclassification or accounting adjustments, and figures are unaudited pending Q3 2026 close
- · Compliance is fragile: Nasdaq will re-test at the next periodic report and delisting may follow if equity falls below $2.5M
23-10-2026
Laser Photonics Corporation (LASE) received a Nasdaq notification on October 20, 2026 that its common stock has closed below the $1.00 minimum bid price for 30 consecutive business days, violating Nasdaq Listing Rule 5550(a)(2). The notice has no immediate effect on listing or trading, and the company has until April 19, 2027 (180 calendar days) to regain compliance by maintaining a closing bid of at least $1.00 for a minimum of 10 consecutive business days. The filing is negative for investors, as the company is at risk of delisting if it fails to cure the deficiency or qualify for a second compliance period.
- · Nasdaq Listing Rule 5810(c)(3)(A) governs the 180-day compliance period, ending April 19, 2027
- · A possible second 180-day compliance period is available if the company meets the market value of publicly held shares requirement and other initial listing standards (excluding bid price), and provides written notice of intent to cure
- · If the company fails to regain compliance or does not qualify for a second period, Nasdaq will issue a delisting determination, which the company may appeal to a hearings panel
- · The company stated it will actively monitor its bid price and consider options to regain compliance, without specifying particular measures
23-10-2026
Century Casinos received a Nasdaq deficiency notice on October 19, 2026, stating its common stock failed to maintain the minimum Market Value of Listed Securities (MVLS) of $35 million under Nasdaq Listing Rule 5550(b)(2) for 30 consecutive business days. The notice has no immediate effect on the stock's listing on the Nasdaq Capital Market, and the company has until April 19, 2027 to regain compliance. The filing notes that failure to regain compliance would lead to a delisting notice, which the company could appeal, though success is not assured.
- · Compliance Date is April 19, 2027, with the Staff possibly requiring a longer compliance period under Rule 5810(c)(3)(H)
- · Company may alternatively regain compliance by meeting stockholders' equity or net income requirements under Rule 5550(b)
- · Company's 10-K for FY2025 and subsequent filings contain additional risk factors
23-10-2026
Medicus Pharma Ltd. (MDCXW) disclosed that it received a Nasdaq delisting determination letter on October 20, 2026, after failing to regain compliance with the $1.00 minimum bid price requirement by the October 19, 2026 deadline, and that Nasdaq was not eligible for a second 180-day compliance period because it does not meet the $5 million stockholders' equity requirement. On October 23, 2026, the company received a Compliance Notice from Nasdaq stating it had regained compliance after the closing bid price was at or above $1.00 for ten consecutive business days (October 12 to October 23, 2026), superseding the delisting determination. The company cautioned that there is no assurance it will maintain compliance going forward.
- · Nasdaq deficiency notice was received April 21, 2026, with a compliance deadline of October 19, 2026
- · Company was denied a second 180-day compliance period because it fails the $5M stockholders' equity requirement
- · Delisting Determination Letter was received October 20, 2026 and rendered moot by the October 23, 2026 Compliance Notice
- · Company is an Ontario-incorporated emerging growth company headquartered in Conshohocken, Pennsylvania
23-10-2026
Innventure, Inc. received a Nasdaq letter on October 23, 2026 stating that its common stock has failed to maintain the $1.00 minimum bid price for thirty consecutive business days ended October 22, 2026, under Nasdaq Listing Rule 5450(a)(1). The company has an initial 180-calendar-day compliance period until April 21, 2027 to regain compliance by closing at or above $1.00 for ten consecutive business days, and may seek an additional 180-day period by transferring to the Nasdaq Capital Market. The letter does not trigger immediate delisting, but there is no assurance the company will regain compliance or secure additional relief.
- · Initial Compliance Period deadline is April 21, 2027
- · Additional Compliance Period requires transfer to Nasdaq Capital Market, satisfaction of market value of publicly held shares and other initial listing standards (excluding bid price), and written notice of intent to cure
- · The company's Form 10-K for FY2025 (filed March 30, 2026) contains relevant risk factors
Get daily alerts with 9 investment signals, 9 risk alerts, 8 opportunities and full AI analysis of all 9 filings
$30/mo after a 14-day free trial — no credit card required. See pricing or explore intelligence streams.
More from: US Corporate Distress Financial Stress SEC Filings
October 21, 2026
US Corporate Distress Financial Stress SEC Filings — October 21, 2026
October 20, 2026
US Corporate Distress Financial Stress SEC Filings — October 20, 2026
October 19, 2026
US Corporate Distress Financial Stress SEC Filings — October 19, 2026
October 16, 2026
US Corporate Distress Financial Stress SEC Filings — October 16, 2026
🇺🇸 More from United States
View all →October 23, 2026
US Pre-Market SEC Filings Roundup — October 23, 2026
US Pre-Market SEC Filings Roundup
October 23, 2026
US Merger & Acquisition SEC Filings — October 23, 2026
US Merger & Acquisition SEC Filings
October 23, 2026
USA Insider Trading Pulse — October 23, 2026
USA Insider Trading Pulse
October 23, 2026
US Corporate Board Director Changes SEC Filings — October 23, 2026
US Corporate Board Director Changes SEC Filings